- Home
- CDTG vs NNVC Comparison
CDTG vs NNVC Comparison
Compare CDTG & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- NNVC
- Stock Information
- Founded
- CDTG 2012
- NNVC 2005
- Country
- CDTG China
- NNVC United States
- Employees
- CDTG N/A
- NNVC N/A
- Industry
- CDTG
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- CDTG
- NNVC Health Care
- Exchange
- CDTG NYSE
- NNVC Nasdaq
- Market Cap
- CDTG 24.5M
- NNVC 22.5M
- IPO Year
- CDTG 2024
- NNVC N/A
- Fundamental
- Price
- CDTG $0.90
- NNVC $1.68
- Analyst Decision
- CDTG
- NNVC
- Analyst Count
- CDTG 0
- NNVC 0
- Target Price
- CDTG N/A
- NNVC N/A
- AVG Volume (30 Days)
- CDTG 137.7K
- NNVC 330.6K
- Earning Date
- CDTG 05-15-2025
- NNVC 05-15-2025
- Dividend Yield
- CDTG N/A
- NNVC N/A
- EPS Growth
- CDTG N/A
- NNVC N/A
- EPS
- CDTG 0.14
- NNVC N/A
- Revenue
- CDTG $29,765,205.00
- NNVC N/A
- Revenue This Year
- CDTG N/A
- NNVC N/A
- Revenue Next Year
- CDTG N/A
- NNVC N/A
- P/E Ratio
- CDTG $5.84
- NNVC N/A
- Revenue Growth
- CDTG N/A
- NNVC N/A
- 52 Week Low
- CDTG $0.52
- NNVC $0.94
- 52 Week High
- CDTG $4.64
- NNVC $2.50
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- NNVC 60.67
- Support Level
- CDTG N/A
- NNVC $1.54
- Resistance Level
- CDTG N/A
- NNVC $1.79
- Average True Range (ATR)
- CDTG 0.00
- NNVC 0.10
- MACD
- CDTG 0.00
- NNVC 0.02
- Stochastic Oscillator
- CDTG 0.00
- NNVC 75.56
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.